We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$13.3M
Cap. Flow
+$60.1M
Cap. Flow %
8.06%
Top 10 Hldgs %
47.22%
Holding
107
New
21
Increased
25
Reduced
20
Closed
22

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$13.6M
2
MRUS
Merus
MRUS
+$10.9M
3
ARVN icon
Arvinas
ARVN
+$9.84M
4
SYRE icon
Spyre Therapeutics
SYRE
+$9.56M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.97M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$13.4M
2
ATXS
Astria Therapeutics
ATXS
+$7.98M
3
VRDN icon
Viridian Therapeutics
VRDN
+$7.94M
4
ONC
BeOne Medicines Ltd
ONC
+$7.86M
5
TERN
Terns Pharmaceuticals
TERN
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.04%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$248M
$7.49M 1%
+2,825,000
New +$8.97M
ORKA
27
Oruka Therapeutics
ORKA
$5.66B
$7.15M 0.96%
368,698
+18,862
+5% +$460K
AXSM icon
28
Axsome Therapeutics
AXSM
$11.5B
$6.35M 0.85%
75,000
-5,000
-6% -$460K
ERAS icon
29
Erasca
ERAS
$6.63B
$6.27M 0.84%
2,499,431
– –
SLNO
30
DELISTED
Soleno Therapeutics
SLNO
$5.84M 0.78%
130,000
+105,000
+420% +$5.44M
ARWR icon
31
Arrowhead Research
ARWR
$10.1B
$5.64M 0.76%
300,000
-25,000
-8% -$515K
BBIO icon
32
BridgeBio Pharma
BBIO
$15.9B
$5.49M 0.74%
200,000
-100,000
-33% -$2.58M
NMRA icon
33
CALL
Neumora Therapeutics
NMRA
$304M
$5.04M 0.67%
+475,000
New +$5.69M
PTGX icon
34
Protagonist Therapeutics
PTGX
$8.68B
$5.02M 0.67%
+130,000
New +$5.67M
MLYS icon
35
Mineralys Therapeutics
MLYS
$2.37B
$4.31M 0.58%
350,000
– –
CATX icon
36
Perspective Therapeutics
CATX
$333M
$4.15M 0.56%
1,300,000
+800,000
+160% +$6.53M
FLNA
37
PUT
Filana Therapeutics
FLNA
$49.3M
$4.1M 0.55%
1,739,400
+290,100
+20% +$5.09M
AVTX icon
38
Avalo Therapeutics
AVTX
$971M
$4.09M 0.55%
550,765
+505,765
+1,124% +$5.41M
PCSC
39
Perceptive Capital Solutions
PCSC
$124M
$3.56M 0.48%
350,000
– –
TVTX icon
40
Travere Therapeutics
TVTX
$5.17B
$3.48M 0.47%
+200,000
New +$3.54M
INSM icon
41
Insmed
INSM
$23.4B
$3.45M 0.46%
50,000
– –
NAMSW icon
42
NewAmsterdam Pharma Warrant
NAMSW
$83.7M
$3.33M 0.45%
237,935
+24,961
+12% +$270K
CMPS
43
Compass Pathways
CMPS
$1.58B
$3.21M 0.43%
850,512
+550,000
+183% +$2.79M
GALT icon
44
PUT
Galectin Therapeutics
GALT
$260M
$3.21M 0.43%
2,492,000
+1,280,600
+106% +$3.07M
CGEM icon
45
Cullinan Oncology
CGEM
$1.09B
$3.21M 0.43%
263,817
– –
VRDN icon
46
Viridian Therapeutics
VRDN
$2.07B
$3.06M 0.41%
159,614
-365,386
-70% -$7.94M
MIRM icon
47
Mirum Pharmaceuticals
MIRM
$7.12B
$2.93M 0.39%
70,742
-4,258
-6% -$177K
CGON icon
48
CG Oncology
CGON
$6.26B
$2.87M 0.38%
+100,000
New +$3.42M
TECX
49
Tectonic Therapeutic
TECX
$604M
$2.69M 0.36%
58,331
– –
BBOT
50
BridgeBio Oncology
BBOT
$676M
$2.63M 0.35%
250,000
– –
1
2
3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Affinity Asset Advisors held 107 positions worth $746M, up 1.8% from $733M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors deployed $60.1M of net new capital in Q4 2024, opening 21 new positions and adding to 25 existing holdings. Its largest new stake was ProQR Therapeutics: 2,825,000 shares worth $7.49M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $7.94M trimmed.

  • Affinity Asset Advisors's largest Q4 2024 buy was ProQR Therapeutics: 2,825,000 shares worth $7.49M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q4 2024, an estimated $13.6M increase.
  • Affinity Asset Advisors's biggest Q4 2024 reduction was Viridian Therapeutics, cutting an estimated $7.94M.
  • Affinity Asset Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $13.4M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $746M portfolio in Q4 2024.
  • Affinity Asset Advisors opened 21 new positions and closed 22 in Q4 2024.
  • Affinity Asset Advisors's portfolio value rose 1.8% quarter-over-quarter to $746M.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.